{"organizations": [], "uuid": "d5337abcd3fc290b3f0e0bc729c60d82d40d0d63", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-apricus-biosciences-announces-outc/brief-apricus-biosciences-announces-outcome-of-vitaros-end-of-review-meeting-with-fda-idUSFWN1RT09W", "country": "US", "domain_rank": 408, "title": "BRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T14:04:00.000+03:00", "replies_count": 0, "uuid": "d5337abcd3fc290b3f0e0bc729c60d82d40d0d63"}, "author": "", "url": "https://www.reuters.com/article/brief-apricus-biosciences-announces-outc/brief-apricus-biosciences-announces-outcome-of-vitaros-end-of-review-meeting-with-fda-idUSFWN1RT09W", "ord_in_thread": 0, "title": "BRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-apricus biosciences", "sentiment": "negative"}, {"name": "apricus biosciences inc", "sentiment": "none"}, {"name": "apricus biosciences", "sentiment": "none"}, {"name": "fda reuters", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 06 AM / Updated 10 minutes ago BRIEF-Apricus Biosciences Announces Outcome Of Vitaros™ End-Of-Review Meeting With FDA Reuters Staff \nApril 16 (Reuters) - Apricus Biosciences Inc: \n* APRICUS BIOSCIENCES ANNOUNCES OUTCOME OF VITAROS™ END-OF-REVIEW MEETING WITH FDA \n* APRICUS BIOSCIENCES INC - COMPANY EVALUATING STRATEGIC ALTERNATIVES \n* APRICUS BIOSCIENCES INC - COMPANY SEEKING PARTNER TO DEVELOP VITAROS IN U.S. \n* APRICUS BIOSCIENCES INC - FDA CONFIRMED DURING MEETING THAT COMPANY SHOULD DEVELOP A NEW VITAROS FORMULATION \n* APRICUS - PRELIMINARY END-OF-REVIEW MEETING MINUTES SUPPORT PLAN TO ADDRESS ISSUES CITED BY FDA IN ITS FEB 15 CRL FOR VITAROS NDA \n* APRICUS BIOSCIENCES - FDA ALSO CONFIRMED 2 NEW PHASE 3 CLINICAL EFFICACY TRIALS WITH REFORMULATED PRODUCT SHOULD BE CONDUCTED PRIOR TO RESUBMITTING NDA \n* APRICUS - IN ADDITION, FDA REQUESTED CERTAIN PHARMACOKINETIC ASSESSMENTS THAT CO EXPECTS CAN BE COMPLETED AS PART OF REQUESTED PHASE 3 PROGRAM \n* APRICUS BIOSCIENCES- FDA SAID CHEMISTRY, MANUFACTURING AND CONTROL SECTION IN RESUBMISSION TO BE UPDATED WITH DATA FROM DEVELOPMENT OF NEW FORMULATION \n* APRICUS - INITIATED DISCUSSIONS WITH INTERESTED PARTIES FOR U.S. VITAROS RIGHTS FOR FINANCIAL TERMS COMMENSURATE WITH DEVELOPMENT STAGE ASSET Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-16T14:04:00.000+03:00", "crawled": "2018-04-16T14:21:15.012+03:00", "highlightTitle": ""}